Provided by Tiger Fintech (Singapore) Pte. Ltd.

Larimar Therapeutics, Inc.

3.03
-0.0500-1.62%
Post-market: 3.030.00000.00%19:55 EDT
Volume:1.92M
Turnover:5.79M
Market Cap:194.00M
PE:-2.03
High:3.14
Open:3.14
Low:2.93
Close:3.08
Loading ...

Larimar Therapeutics (LRMR) Gets a Buy from Guggenheim

TIPRANKS
·
26 Jun

Larimar Therapeutics Inc : Wedbush Cuts Target Price to $15 From $17

THOMSON REUTERS
·
24 Jun

JonesTrading Reaffirms Their Buy Rating on Larimar Therapeutics (LRMR)

TIPRANKS
·
24 Jun

Wedbush Adjusts Larimar Therapeutics Price Target to $15 From $17, Maintains Outperform Rating

MT Newswires Live
·
23 Jun

Larimar Therapeutics Announces FDA Safety Database Recommendations and Refines Timeline for BLA Submission for Friedreich's Ataxia Program

Reuters
·
23 Jun

Larimar Therapeutics Inc - Adolescent Pk Run-in Data Expected in September 2025

THOMSON REUTERS
·
23 Jun

Larimar Therapeutics Inc - Bla Submission for Accelerated Approval Planned in Q2 2026

THOMSON REUTERS
·
23 Jun

Larimar Therapeutics Announces FDA Recommendations on Safety Database, and Other Details of Nomlabofusp Bla Submission for Friedreich’s Ataxia Program

THOMSON REUTERS
·
23 Jun

Larimar Therapeutics Inc - Ole Data Expected in September 2025 From 30-40 Participants

THOMSON REUTERS
·
23 Jun

BRIEF-Larimar Therapeutics announces regulatory update call on Nomlabofusp Program

Reuters
·
21 Jun

Larimar Therapeutics Announces Regulatory Update Call on the Nomlabofusp Program for the Treatment of Friedreich’s Ataxia

THOMSON REUTERS
·
21 Jun

Larimar Therapeutics Inc. Conducted Annual Stockholders Meeting Virtually

Reuters
·
14 May

Analysts Offer Insights on Healthcare Companies: BioNTech SE (BNTX), PTC Therapeutics (PTCT) and Larimar Therapeutics (LRMR)

TIPRANKS
·
06 May

Analysts Offer Insights on Healthcare Companies: Bausch Health Companies (BHC), Humana (HUM) and Larimar Therapeutics (LRMR)

TIPRANKS
·
01 May

Larimar Therapeutics Q1 EPS $(0.46) Misses $(0.42) Estimate

Benzinga
·
30 Apr

BRIEF-Larimar Therapeutics Q1 Net Income USD -29.281 Million

Reuters
·
30 Apr

Larimar Therapeutics Q1 Basic EPS USD -0.46

THOMSON REUTERS
·
30 Apr

Larimar Therapeutics Q1 Operating Expenses USD 31.188 Million

THOMSON REUTERS
·
30 Apr

Larimar Therapeutics Reports First Quarter 2025 Financial Results

GlobeNewswire
·
30 Apr

Is Larimar Therapeutics (NASDAQ:LRMR) In A Good Position To Invest In Growth?

Simply Wall St.
·
28 Mar